Fremanezumab is a calcitonin-gene related peptide (CGRP) pathway monoclonal antibody that is FDA approved for adults with ...

Instead, Qulipta belongs to a group of drugs called calcitonin gene-related peptide (CGRP) antagonists. Qulipta helps prevent migraine episodes, while triptans help treat migraine episodes.

Atogepant, a new oral prescription drug, shows promise in preventing migraines by targeting CGRP receptors, reducing migraine ...

Compared with the use of other migraine medications, use of erenumab did not increase cardiovascular or cerebrovascular risks.

All participants received their allocated digital treatment as an add-on to acute and/or non–migraine-specific preventive medications. Exclusion criteria included use of calcitonin gene–related ...

Atogepant was approved last September as Qulipta for migraine prevention in the US ... among people who don't respond to injectable CGRP drugs or have needle phobia. "Far too many people ...

At AAN 2025, three posters presented the sustained long-term efficacy and real-world impact of Lundbeck’s Vyepti for migraine ...

Zavegepant was effective in relieving acute migraine symptoms, with a safety profile similar to other oral calcitonin gene-related peptide receptor antagonists.

If approved for an expanded pediatric indication, AJOVY would be the first calcitonin gene-related peptide (CGRP) antagonist for migraine ...

If approved, AJOVY would be the only calcitonin gene-related peptide (CGRP) antagonist for migraine prevention in adults and episodic migraine prevention in pediatric patients, helping to address ...